Last reviewed · How we verify
Lauromacrogol
Lauromacrogol is a Small molecule drug developed by Shanghai Zhongshan Hospital. It is currently in Phase 3 development.
Lauromacrogol is a small molecule with an unknown mechanism of action, according to ChEMBL. It is also known as Aethoxysklerol, Asclera, Laureth 9, and Polidocanol, which is used to treat various conditions including cutaneous warts, varicose veins, and hemorrhoids.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Lauromacrogol |
|---|---|
| Sponsor | Shanghai Zhongshan Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Varithena Versus Endothermal Ablation of the Great Saphenous Vein (VERITAS) (PHASE4)
- Comparison of Radiofrequency Ablation With Concomitant or Staged Treatment for Tributary Varicose Veins (NA)
- Caprini Score in Venous Surgery: a Prospective Cohort Study
- Comparative Study Between Sclerosing Agents Used in Treatment of Vascular Malformation (NA)
- Furosemide-Digoxin vs. Polidocanol for Cutaneous Warts (PHASE2)
- Polidocanol Foam With or Without Transdermal Laser for Varicose Veins: Randomized Clinical Trial (NA)
- Efficacy of the SALFOAM 3% Method Compared to the Conventional Polidocanol Foam Method (Tessari Method) for Treating Lower Limb Varicose Veins (NA)
- Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lauromacrogol CI brief — competitive landscape report
- Lauromacrogol updates RSS · CI watch RSS
- Shanghai Zhongshan Hospital portfolio CI
Frequently asked questions about Lauromacrogol
What is Lauromacrogol?
Who makes Lauromacrogol?
What development phase is Lauromacrogol in?
Related
- Manufacturer: Shanghai Zhongshan Hospital — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing